Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06593665 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Intrathecal Morphine Versus Intravenous Methadone for Postoperative Analgesia Following Retroperitoneal Lymph Node Dissection.

Study acronym: RPLND
StatusRecruiting
PhasePhase 3
Started2024-09-10
View on ClinicalTrials.gov ↗

Amendment history

2026-02-11
Study Identification, Study Status, Sponsor/Collaborators, Oversight, Contacts/Locations v2
Study sitescontacts updated at 1 of 2 sites
2024-11-11
Not Yet Recruiting→Recruiting Study Status, Oversight, Study Design, Arms and Interventions, Contacts/Locations v1
Trial statusNot Yet Recruiting→Recruiting
PhaseNot applicable→Phase 3
Completion date2027-01-31→2026-12-31
Study sites1→2
InterventionsInrathecal Morphine (Other), Intravenous Methadone (Other)→Inrathecal Morphine (Drug), Intravenous Methadone (Drug)
2024-09-09
Original filing
This randomization study is to compare both intrathecal morphine and intravenous methadone, which are both standard of care, for pain management in patients undergoing retroperitoneal lymph node dissections for primary testicular cancer. Investigators plan to compare their analgesic effectiveness at different postoperative time intervals.
Trial Details
NCT Number NCT06593665
Lead Sponsor Indiana University
Conditions Testicular Cancer
Enrollment 142 participants
Start Date 2024-09-10
Primary Completion 2026-12-31 (estimated)
Study Completion 2026-12-31 (estimated)
Updated on ClinicalTrials.gov 2026-02-13